Cargando…

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study

BACKGROUND: We present findings from the multicenter, double-blind Phase 3 study, CENTURION. This study was designed to assess the efficacy of and consistency of response to lasmiditan in the acute treatment of migraine across four attacks. METHODS: Patients were randomized 1:1:1 to one of three tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashina, Messoud, Reuter, Uwe, Smith, Timothy, Krikke-Workel, Judith, Klise, Suzanne R, Bragg, Sonja, Doty, Erin G, Dowsett, Sherie A, Lin, Qun, Krege, John H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961651/ https://www.ncbi.nlm.nih.gov/pubmed/33541117 http://dx.doi.org/10.1177/0333102421989232

Ejemplares similares

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
por: Smith, Timothy, et al.
Publicado: (2020)

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
por: Loo, Li Shen, et al.
Publicado: (2019)

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
por: Doty, Erin G., et al.
Publicado: (2022)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
por: Brandes, Jan Lewis, et al.
Publicado: (2019)

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies
por: Ashina, Messoud, et al.
Publicado: (2019)

Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial
por: Yu, Tingmin, et al.
Publicado: (2022)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
por: Doty, Erin Gautier, et al.
Publicado: (2019)

Provoked versus spontaneous migraine attacks: pathophysiological similarities and differences
por: Ashina, Håkan, et al.
Publicado: (2022)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

The new centurions /
por: Wambaugh, Joseph
Publicado: (1972)

Los nuevos centuriones
por: Wambaugh, Joseph
Publicado: (1971)

Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis
por: Basutkar, Roopa Satyanarayan, et al.
Publicado: (2021)

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
por: Lipton, Richard B., et al.
Publicado: (2020)

Lasmiditan: A New Promising Drug in Migraine
por: Prakash, Sanjay, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

The influence of weather on migraine – are migraine attacks predictable?
por: Hoffmann, Jan, et al.
Publicado: (2015)

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
por: Loo, Li Shen, et al.
Publicado: (2019)

Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study
por: Diener, Hans-Christoph, et al.
Publicado: (2021)

Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine
por: Ashina, Messoud
Publicado: (2022)

The changing faces of migraine
por: Martelletti, Paolo, et al.
Publicado: (2019)

The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings
por: Tepper, Stewart J., et al.
Publicado: (2019)

Primary anterior punctal malposition presenting as Centurion syndrome
por: Alam, Md Shahid, et al.
Publicado: (2017)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans
por: Do, Thien Phu, et al.
Publicado: (2023)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0qme3g1a19a2shnq733p3hn9qn